Evidence map›Paper›PMID 41009819›Full record

ReviewInternational journal of molecular sciences2025

Tumor Innervation: From Bystander to Emerging Therapeutic Target for Cancer.

Zoey Zeyuan Ji, Max Kam-Kwan Chan, Philip Chiu-Tsun Tang, Calvin Sze-Hang Ng, Chunjie Li, Dongmei Zhang, David J Nikolic-Paterson, Ka-Fai To, Xiaohua Jiang, Patrick Ming-Kuen Tang

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. The authors respond to feedback onFrontiers in oncology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zoey Zeyuan JiDepartment of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong.
Max Kam-Kwan ChanDepartment of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong.
Philip Chiu-Tsun TangDepartment of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong.ORCID 0000-0002-1768-1127
Calvin Sze-Hang NgDepartment of Surgery, The Chinese University of Hong Kong, Hong Kong.ORCID 0000-0002-8074-0900
Chunjie LiDepartment of Head and Neck Oncology, West China Hospital of Stomatology, Sichuan University, Chengdu 610065, China.
Dongmei ZhangCollege of Pharmacy, Jinan University, Guangzhou 510632, China.
David J Nikolic-PatersonDepartment of Nephrology and Monash University Department of Medicine, Monash Medical Centre, Clayton, VIC 3168, Australia.ORCID 0000-0001-5734-2931
Ka-Fai ToDepartment of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong.
Xiaohua JiangKey Laboratory for Regenerative Medicine of the Ministry of Education of China, School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong.ORCID 0000-0002-7372-4961
Patrick Ming-Kuen TangDepartment of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong.ORCID 0000-0002-3194-3736

Funding

CUHK Strategic Seed Funding for Collaborative Research Scheme 178896941CU Medicine Passion for Perfection Scheme PFP202210-004Direct Grant for Research 4054844, 2025.142Faculty Innovation Award 2019 4620528Health and Medical Research Fund 10210726, 11220576Innovation and Technology Fund ITS/177/22FP, ITS/016/23MS, ITS/301/23Peter Hung Pain Research Institute Research Fund 8423011Postdoctoral Fellowship Scheme NL/LT/PDFS2022/0360/22lt, WW/PDFS2023/0640/23en, FPFS/23-24/046Research Grants Council of Hong Kong C4013-24GF, 24102723, 14107624RGC Postdoctoral Fellowship Scheme PDFS2122-4S06, PDFS2425-4S07
6 · The paper itself

Abstract

Innervation is ubiquitous in diseased tissues, including cancer. Increasing evidence suggests that innervation not only plays a direct role in cancer pain, but is also closely related to disease progression, including cancer growth, metastasis, and drug resistance. At the molecular level, tumor-associated nerves can interact with cancer cells and the tumor microenvironment through neurotrophic factors, thereby promoting tumor occurrence and development, and represent a potential intervention for solid tumors with nerve enrichment. By dissecting the transcriptome dynamics of cancer-associated neurons with single cell resolution, numbers of novel therapeutic targets for tumor denervation have been uncovered, including a novel phenomenon-Macrophage to Neuron-like cell Transition (MNT). This review systematically summarizes the latest research findings of tumor denervation, from molecular mechanisms to the innovative denervation strategies, paving the way for novel, safe, and effective cancer treatments in the clinic.

Indexed as

NeoplasmsAnimalsHumansNeuronsTumor Microenvironmentdenervation therapytumor innervationtumor–nerve crosstalk

Identifiers

PMID41009819
PMCPMC12471000

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.